Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab
Background. Pertuzumab disrupts heterodimerization between human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), HER3, a
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2017
|
| In: |
Annals of oncology
Year: 2017, Volume: 28, Issue: 4, Pages: 761-768 |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdw695 |
| Online Access: | Verlag, LF, Volltext: http://dx.doi.org/10.1093/annonc/mdw695 Verlag, LF, Volltext: https://academic.oup.com/annonc/article/28/4/761/2837420 
|
| Author Notes: | S.M. Swain, A. Schneeweiss, L. Gianni, J.J. Gao, A. Stein, M. Waldron-Lynch, S. Heeson, M.S. Beattie, B. Yoo, J. Cortes & J. Baselga |
| Summary: | Background. Pertuzumab disrupts heterodimerization between human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), HER3, a |
|---|---|
| Item Description: | Published: 05 January 2017 Gesehen am 20.06.2018 |
| Physical Description: | Online Resource |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdw695 |